Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Aug;22(4):397-407.
doi: 10.1007/s40291-018-0344-x.

Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis

Mingming Liang  1 , Yun Zhang  1 , Chenyu Sun  2 , Feras Kamel Rizeq  3 , Min Min  1 , Tingting Shi  1 , Yehuan Sun  4   5
Affiliations
Meta-Analysis

Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis

Mingming Liang et al. Mol Diagn Ther. 2018 Aug.

Abstract

Introduction: The association between the checkpoint kinase 2*1100delC (CHEK2*1100delC) and breast cancer has been extensively explored.

Objective: In light of the recent publication of studies on these specific findings, particularly regarding male patients with breast cancer, we performed an updated meta-analysis to investigate a more reliable estimate.

Methods: This meta-analysis included 26 published studies selected in a search of electronic databases up to January 2018, including 118,735 breast cancer cases and 195,807 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association between 1100delC and breast cancer.

Results: Meta-analysis results suggested that 1100delC contributed to an increased breast cancer risk in overall populations (OR 2.89; 95% CI 2.63-3.16). Subgroup analysis found ORs of 3.13 (95% CI 1.94-5.07) for male breast cancer, 2.88 (95% CI 2.63-3.16) for female breast cancer, 2.87 (95% CI 1.85-4.47) for early-onset breast cancer, 2.92 (95% CI 2.65-3.22) for invasive breast cancer, and 3.21 (95% CI 2.41-4.29) for familial breast cancer. The sensitivity analysis suggested that results of this meta-analysis were generally robust.

Conclusion: CHEK2*1100delC is associated with an increased risk of both female and male breast cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer.
    McClurg DP, Urquhart G, McGoldrick T, Chatterji S, Miedzybrodzka Z, Speirs V, Elsberger B. McClurg DP, et al. Cancers (Basel). 2022 Jun 28;14(13):3175. doi: 10.3390/cancers14133175. Cancers (Basel). 2022. PMID: 35804947 Free PMC article. Review.
  • Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.
    Allen I, Hassan H, Sofianopoulou E, Eccles D, Turnbull C, Tischkowitz M, Pharoah P, Antoniou AC. Allen I, et al. Br J Cancer. 2022 Nov;127(9):1660-1669. doi: 10.1038/s41416-022-01940-1. Epub 2022 Sep 17. Br J Cancer. 2022. PMID: 36115878 Free PMC article.
  • ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.
    Stolarova L, Kleiblova P, Zemankova P, Stastna B, Janatova M, Soukupova J, Achatz MI, Ambrosone C, Apostolou P, Arun BK, Auer P, Barnard M, Bertelsen B; Biobank Japan; Blok MJ, Boddicker N, Brunet J, Burnside ES, Calvello M, Campbell I, Chan SH, Chen F, Chiang JB, Coppa A, Cortesi L, Crujeiras-González A; Consortium CZECANCA; De Leeneer K, De Putter R, DePersia A, Devereux L, Domchek S, Efremidis A, Engel C, Ernst C, Evans DGR, Feliubadaló L, Fostira F, Fuentes-Ríos O, Gómez-García EB, González S, Haiman C, Hansen TVO, Hauke J, Hodge J, Hu C, Huang H, Ishak NDB, Iwasaki Y, Konstantopoulou I, Kraft P, Lacey J, Lázaro C, Li N, Lim WK, Lindstrom S, Lori A, Martinez E, Martins A, Matsuda K, Matullo G, McInerny S, Michailidou K, Montagna M, Monteiro ANA, Mori L, Nathanson K, Neuhausen SL, Nevanlinna H, Olson JE, Palmer J, Pasini B, Patel A, Piane M, Poppe B, Radice P, Renieri A, Resta N, Richardson ME, Rosseel T, Ruddy KJ, Santamariña M, Dos Santos ES, Teras L, Toland AE, Trentham-Dietz A, Vachon CM, Volk AE, Weber-Lassalle N, Weitzel JN, Wiesmuller L, Winham S, Yadav S, Yannoukakos D, Yao S, Zampiga V, Zethoven M, Zhang ZW, Zima T, Spurdle AB, Vega A, Rossing M, Del Valle J, De Nicolo… See abstract for full author list ➔ Stolarova L, et al. Clin Cancer Res. 2023 Aug 15;29(16):3037-3050. doi: 10.1158/1078-0432.CCR-23-0212. Clin Cancer Res. 2023. PMID: 37449874 Free PMC article.
  • Postmastectomy Reconstruction in Male Breast Cancer.
    Deldar R, Sayyed AA, Towfighi P, Aminpour N, Sogunro O, Son JD, Fan KL, Song DH. Deldar R, et al. Breast J. 2022 Mar 29;2022:5482261. doi: 10.1155/2022/5482261. eCollection 2022. Breast J. 2022. PMID: 35711890 Free PMC article. Review.
  • Male breast cancer: a disease distinct from female breast cancer.
    Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Gucalp A, et al. Breast Cancer Res Treat. 2019 Jan;173(1):37-48. doi: 10.1007/s10549-018-4921-9. Epub 2018 Sep 28. Breast Cancer Res Treat. 2019. PMID: 30267249 Free PMC article. Review.
See all "Cited by" articles

References

    1. J Clin Oncol. 2010 Apr 20;28(12):2114-22 - PubMed
    1. Eur J Cancer. 2005 Aug;41(12):1819-23 - PubMed
    1. N Engl J Med. 2016 Aug 4;375(5):443-53 - PubMed
    1. J Clin Oncol. 2007 Jan 1;25(1):57-63 - PubMed
    1. Int J Cancer. 2004 Jan 20;108(3):475-6 - PubMed

LinkOut - more resources

  NODES
Association 6
chat 2
Project 1
twitter 2